Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.51 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 8/20 | 0.50 |
| ▸ | SIRT6 | Q8N6T7 | 3/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | HTR6 | P50406 | 1/20 | 0.47 |
| ▸ | BCL2A1 | Q16548 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL520215 | 0.84 | SIRT6 (0.69) | L3MBTL1MAPK1MAPTSIRT6ALDH1A1 | |
| SCHEMBL15994494 | 0.84 | MAPT (0.46) | L3MBTL1MAPK1LMNAMAPTSIRT6 | |
| SCHEMBL4772717 | 0.83 | MAPT (0.72) | L3MBTL1MAPK1LMNAOPRM1OPRD1 | |
| SCHEMBL22652221 | 0.83 | L3MBTL1 (0.51) | L3MBTL1MAPK1LMNAOPRM1OPRD1 | |
| SCHEMBL30679043 | 0.83 | SIRT6 (0.72) | L3MBTL1MAPK1LMNAOPRM1OPRD1 | |
| SCHEMBL4762192 | 0.83 | MAPT (0.57) | L3MBTL1MAPK1LMNAOPRM1OPRD1 | |
| SCHEMBL22652109 | 0.83 | MAPT (0.49) | L3MBTL1MAPK1LMNAOPRM1OPRD1 | |
| SCHEMBL2927491 | 0.82 | GAA (0.55) | L3MBTL1MAPK1LMNAOPRM1OPRD1 | |
| SCHEMBL4925099 | 0.81 | HTR6 (0.57) | L3MBTL1MAPK1LMNAMAPTSIRT6 | |
| SCHEMBL18092535 | 0.81 | LMNA (0.49) | L3MBTL1MAPK1LMNAOPRM1OPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3102571-A1 | SUBSTITUTED PYRIMIDINES USEFUL AS EGFR-T790M KINASE INHIBITORS | Jiangsu Medolution Ltd. (CN) | 2016-12-14 | — | — | EP | disclosed |
| WO-2015117547-A1 | SUBSTITUTED PYRIMIDINES USEFUL AS EGFR-T790M KINASE INHIBITORS | JIANGSU MEDOLUTION LIMITED (CN) | 2015-08-13 | — | — | WO | disclosed |
| EP-1976847-B1 | PYRIMIDINYL ARYL UREA DERIVATIVES BEING FGF INHIBITORS | NOVARTIS AG (CH) | 2015-06-17 | — | — | EP | disclosed |
| US-8759517-B2 | Pyrirnidinyl aryl urea derivatives being FGF inhibitors | NOVARTIS AG (CH) | 2014-06-24 | — | — | US | disclosed |
| US-20130030171-A1 | Pyrimidinyl Aryl Urea Derivatives being FGF Inhibitors | NOVARTIS AG (CH) | 2013-01-31 | — | — | US | disclosed |
| US-8293746-B2 | Pyrimidinyl aryl urea derivatives being FGF inhibitors | NOVARTIS AG (CH) | 2012-10-23 | — | — | US | disclosed |
| CN-101336237-A | Pyrimidinyl aryl urea derivatives being fgf inhibitors | NOVARTIS AG (CH) | 2008-12-31 | — | — | CN | disclosed |
| US-20080312248-A1 | Pyrimidinyl Aryl Urea Derivatives Being Fgf Inhibitors | NOVARTIS AG | 2008-12-18 | — | — | US | disclosed |
| EP-1976847-A2 | PYRIMIDINYL ARYL UREA DERIVATIVES BEING FGF INHIBITORS | Novartis AG (CH) | 2008-10-08 | — | — | EP | disclosed |
| WO-2007071752-A2 | PYRIMIDINYL ARYL UREA DERIVATIVES BEING FGF INHIBITORS | NOVARTIS AG (CH) | 2007-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080312248-A1 | Pyrimidinyl Aryl Urea Derivatives Being Fgf Inhibitors | FGFR1, FGF1, FGF2 | L3MBTL1 4564/4885MAPK1 50/4885LMNA 4188/4885 |
| US-20130030171-A1 | Pyrimidinyl Aryl Urea Derivatives being FGF Inhibitors | FGFR1, FGF1, FGF2 | L3MBTL1 4564/4885MAPK1 50/4885LMNA 4188/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.